Cheng Jianjun Assistant Professor
Degree : Affiliation : Position : Honor : Final education : Graduate School : Tel :021-20685237 Fax : Office : Add : Email Research Group: Group Website: Research Area:GPCR-targeted drug discovery

Education Background

  • 2001/09-2005/06, Shandong University, BS
  • 2005/09-2010/07, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Ph.D.

Working Experience

  • 2010/07-2013/10, Shanghai Huilun Life Sciences & Technology, Senior Scientist
  • 2013/11-2016/03, University of Illinois at Chicago, Postdoctoral Research Associate
  • 2016/03-2022/06, ShanghaiTech University, iHuman Institute, Principal Investigator
  • 2022/07-present, ShanghaiTech University, School of Life Science and Technology/iHuman Institute, Assistant Professor (TENURE-TRACK)

Research Interests

Research Achievement

1. Structure-based discovery of non-hallucinogenic psychedelic analog IHCH-7086 as a novel antidepressant drug candidate (Science 2022).

2. Structure-based discovery of highly selective dopamine D2 receptor partial agonist IHCH-7041 as a novel preclinical anti-schizophrenia drug candidate (Nature Neuroscience 2022, cover story).

3. PCPMA-based discovery of highly selective serotonin 2C agonists with anti-schizophrenia effects (J Med Chem 2015; 2016a; 2016b); highly selective dopamine D3 ligands (J Med Chem 2020); dopamine D2 partial agonists with anti-schizophrenia effects (J Med Chem 2021).

4. Discovery of dual-acting tumor immunotherapeutics targeting the adenosine A2a receptor and histone deacetylases (J Med Chem 2021; Eur J Med Chem 2022).

Representative Publications

  1. Duan W, Cao D, Wang S*Cheng J*Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants. Chem Rev 2024, 124, 124-163.

  2. Li H, Cheng J*2-Phenylcyclopropylmethylamine (PCPMA) as a privileged scaffold for central nervous system drug design. Bioorg Med Chem Lett 2024, 101, 129654.

  3. Liu R, Duan W, Yan W, Zhang J, Cheng J*Design and synthesis of tri-substituted pyrimidine derivatives as bifunctional tumor immunotherapeutic agents targeting both A2A adenosine receptors and histone deacetylases. Chin Chem Lett 2024, 35, 108136.

  4. Mao J#, Cui Y#, Wang H, Duan W, Liu Z-J, Hua T, Zhou N*, Cheng J*.  Design and Synthesis of Novel GPR139 Agonists with Therapeutic Effects in Mouse Models of Social Interaction and Cognitive Impairment. J Med Chem 2023, 66, 14011–14028.

  5. Zhang J#, Feng D#Cheng J*, Wuthrich K*. Adenosine A2A Receptor (A2AAR) Ligand Screening Using the 19F-NMR Probe FPPA. J Am Chem Soc 2023, 145, 15061−15064.

  6. Liu R#, Qi J#, Wang H, Fan L, Zhang P, Yu J, Tan L, Wang S*Cheng J*Transformation of a Dopamine D2 Receptor Agonist to Partial Agonists as Novel Antipsychotic Agents. J Med Chem 2023, 66, 62746287.

  7. Sun N#, Yang K#, Yan W#, Yao M, Yu C, Duan W, Gu X, Guo D, Jiang H, Xie C*Cheng J*Design and Synthesis of Triazole-Containing HDAC Inhibitors That Induce Antitumor Effects and Immune Response. J Med Chem 2023, 66, 48024826.

  8. Gu X, Yuan H, Zhao W, Sun N, Yan W, Jiang C, He Y, Liu H, Cheng J*, Guo D*. Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V2 Receptor in In Vitro, Ex Vivo, and In Vivo Models of ADPKD.J Med Chem 2023, 66, 1454−1466.

  9. Wang J#, Wu M#, Chen Z#, Wu L, Wang T, Cao D, Wang H, Liu S, Xu Y, Li F, Liu J, Chen N, Zhao S, Cheng J*, Wang S*, Hua T*. The unconventional activation of the muscarinic acetylcholine receptor M4R by diverse ligands. Nat Comm 2022, 13, 2855.

  10. Zhang H#, Yan W#, Sun Y#, Yuan H, Su L, Cao X, Wang P, Xu Z, Hu Y, Wang Z, Wang Y, Fu K, Sun Y, Chen Y*, Cheng J*, Guo, D*. Long Residence Time at the Vasopressin V2 Receptor Translates into Superior Inhibitory Effects in ex vivo and in vivo Models of Autosomal Dominant Polycystic Kidney Disease. J Med Chem2022, 65, 7717−7728.

  11. Zhang J#, Luo Z#, Duan W, Yang K, Ling L, Yan W, Liu R, Wüthrich K, Jiang H*, Xie C*, Cheng J*. Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. Eur J Med Chem2022, 236, 114326.

  12. Cao D#, Yu J#, Wang H#, Luo Z#, Liu X#, He L, Qi J, Fan L, Tang L, Chen Z, Li J, Cheng J*, Wang S*. Structure-based discovery of non-hallucinogenic psychedelic analogs. Science 2022, 375, 403-411.

  13. Chen Z#, Fan L#, Wang H#, Yu J#, Lu D#, Qi J, Nie F, Luo Z, Liu Z, Cheng J*, Wang S*. Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties. Nat Neurosci 2022, 25, 39–49.

  14. Yan W#, Fan L#, Yu J, Liu R, Wang H, Tan L, Wang S*, Cheng J*2-Phenylcyclopropyl-methylamine (PCPMA) derivatives as dopamine D2 receptor partial agonists: Design, synthesis and biological evaluation.J Med Chem 2021, 64, 17239-17258.

  15. Yan W#, Ling L#, Wu Y, Yang K, Liu R, Zhang J, Zhao S, Zhong G, Zhao S, Jiang H*, Xie C*, Cheng J*Structure-based design of dual-acting compounds targeting adenosine A2A receptor and histone deacetylase as novel tumor immunotherapeutic agents. J Med Chem 2021, 64, 16573-16597.

  16. Duan W#, Sun Y#, Wu M#, Zhang Z, Zhang T, Wang H, Li F, Yang L, Xu Y, Liu Z-J, Hua T*, Nie H*, Cheng J*. Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis. Eur J Med Chem 2021, 226, 113878.

  17. Zhang J, Yan W, Duan W, Wüthrich K, Cheng J*. Tumor Immunotherapy Using A2A Adenosine Receptor Antagonists. Pharmaceuticals 2020, 13, 237.

  18. Fan L#, Tan L#, Chen Z, Qi J, Nie F, Luo Z,Cheng J*Wang S*. Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands. Nat Commun 2020, 11, 1074.

  19. Chan HCS#, Xu Y#, Tan L#, Vogel H, Cheng J*, Wu D*, Yuan S*. Enhancing the Signaling of GPCRs via Orthosteric Ions, ACS Cent Sci 2020, 6, 274282.

  20. Tan L#, Zhou Q#, Yan W, Sun J, Kozikowski AP, Zhao S, Huang X-P*, Cheng J*. Design and Synthesis of Bitopic 2 Phenylcyclopropylmethylamine (PCPMA) Derivatives as Selective Dopamine D3 Receptor Ligands. J Med Chem 2020, 63, 4579-4602.






Group Member

  • Name:Huan Wang
    Position:Research Assistant Professor
  • Name:Wenzhong Yan
    Position:Research Assistant Professor
  • Name:Jinfeng Zhang
  • Name:Huiqiong Li
    Position:Ph.D student
  • Name:Jianhang Mao
    Position:Master student
  • Name:Rongyan Li
    Position:Master student
  • Name:Yangyang Liu
    Position:Master student

Group Photo